Effects of dietary fiber on inflammatory bowel disease

被引:179
作者
Galvez, J [1 ]
Rodríguez-Cabezas, ME [1 ]
Zarzuelo, A [1 ]
机构
[1] Univ Granada, Dept Pharmacol, Sch Pharm, E-18071 Granada, Spain
关键词
dietary fiber; experimental colitis; inflammatory bowel disease; prebiotic; review; short-chain fatty acid;
D O I
10.1002/mnfr.200500013
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The chronic idiopathic inflammatory bowel diseases (IBDs), namely Crohn's disease and ulcerative colitis, appear to be derived from an inappropriate reaction towards a luminal agent, most probably driven by the intestinal microflora, which upregulates the synthesis and release of different pro-inflammatory mediators, thus contributing to tissue damage that characterizes these intestinal conditions. Several studies have reported that IBD is associated with impairment in short-chain fatty acid (SCFA) production, mainly acetate, propionate, and butyrate. They are produced in the large bowel by anaerobic bacterial fermentation of undigested dietary carbohydrates and fiber polysaccharides, with butyrate being considered as the major fuel source for colonocytes. These SCFAs have been proposed to play a key role in the maintenance of colonic homeostasis. Therefore, it is reasonable to consider therapeutic approaches that increase colonic SCFA production, as it can be achieved by administration of dietary fiber to IBD patients. Unfortunately, there is quite limited documentation of efficacy of dietary fiber in properly designed trials. This review discusses the rationale, available evidence for the use of dietary fiber and its mechanisms of action in the treatment and prevention of IBDs.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 79 条
[21]   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Brigidi, P ;
Matteuzzi, D ;
Bazzocchi, G ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2000, 119 (02) :305-309
[22]   Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209
[23]   Increasing fecal butyrate in ulcerative colitis patients by diet:: Controlled pilot study [J].
Hallert, C ;
Björck, I ;
Nyman, M ;
Pousette, A ;
Grännö, C ;
Svensson, H .
INFLAMMATORY BOWEL DISEASES, 2003, 9 (02) :116-121
[24]   ISPAGHULA HUSK MAY RELIEVE GASTROINTESTINAL SYMPTOMS IN ULCERATIVE-COLITIS IN REMISSION [J].
HALLERT, C ;
KALDMA, M ;
PETERSSON, BG .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1991, 26 (07) :747-750
[25]   SPONTANEOUS INFLAMMATORY DISEASE IN TRANSGENIC RATS EXPRESSING HLA-B27 AND HUMAN BETA-2M - AN ANIMAL-MODEL OF HLA-B27-ASSOCIATED HUMAN DISORDERS [J].
HAMMER, RE ;
MAIKA, SD ;
RICHARDSON, JA ;
TANG, JP ;
TAUROG, JD .
CELL, 1990, 63 (05) :1099-1112
[26]  
Hanai H, 2004, INT J MOL MED, V13, P643
[27]   Use of Probiotics in the treatment of inflammatory bowel disease [J].
Hart, AL ;
Stagg, AJ ;
Kamm, MA .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2003, 36 (02) :111-119
[28]   ATTENUATION OF EPITHELIAL INJURY IN ACUTE EXPERIMENTAL COLITIS BY IMMUNOMODULATORS [J].
HIGA, A ;
MCKNIGHT, GW ;
WALLACE, JL .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 239 (1-3) :171-176
[29]   The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation [J].
Hinnebusch, BF ;
Meng, SF ;
Wu, JT ;
Archer, SY ;
Hodin, RA .
JOURNAL OF NUTRITION, 2002, 132 (05) :1012-1017
[30]   Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation [J].
Huang, N ;
Katz, JP ;
Martin, DR ;
Wu, GD .
CYTOKINE, 1997, 9 (01) :27-36